The UK Pen Needles Market was valued at $100.46 Million in 2024 and projected to reach to $166.32 Million by 2029, representing a compound annual growth rate of 8.8%. The UK pen needles market is positioned for sustained growth through 2029, supported by increasing diabetes diagnoses and NHS commitment to improving patient outcomes.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The UK pen needles market is valued at $100.46 million in 2024, with a projected CAGR of 8.8% through 2029, reaching $166.32 million by forecast end.
Rising diabetes prevalence across the UK population is a primary growth catalyst, with increasing numbers of patients requiring injectable insulin and GLP-1 therapies for disease management.
NHS initiatives promoting diabetes management and healthcare modernization are accelerating adoption of convenient self-administration devices, particularly among Type 2 diabetes patients.
Growing patient preference for user-friendly, convenient self-injection devices is driving demand for advanced pen needle solutions with improved safety features and ease of use.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Develops a wide range of pen needles designed for insulin and GLP-1 delivery, including safety-engineered and ultra-fine variants compatible with multiple pen systems. | Ensures precise dosage, minimizes needlestick injuries, and enhances patient comfort and adherence in diabetes management. |
|
|
Manufactures high-quality pen needles optimized for its insulin pens and GLP-1 therapies, focusing on smooth penetration and ease of use. | Improves injection comfort, ensures consistent insulin delivery, and promotes better self-management among diabetic patients. |
|
|
Offers pen needles under the “Omnican” brand, designed for accurate insulin injection with ergonomic grip and minimal penetration force. | Provides enhanced safety, precision, and comfort, reducing anxiety associated with daily injections. |
|
|
Specializes in pen needles compatible with various injection pens and integrates user-friendly, low-pain technology for chronic disease management. | Enhances user experience through ergonomic design, reliable connectivity with injection devices, and improved compliance. |
|
|
Produces fine-gauge pen needles featuring advanced Japanese micro-needle technology for accurate and gentle drug delivery. | Reduces injection pain, improves dosing precision, and supports patient confidence in self-injection therapy. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | SAFETY PEN NEEDLES (Type) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 9.2% from 2024 to 2029 |
| Largest Segment | STANDARD PEN NEEDLES (Type) |
| Market Size Base Year (Billions) | ~USD 1.82 (2024) |
| Revenue Forecast (Billions) | ~USD 3.08 (2029) |
| Segments Covered | Type, Length, Application, Mode Of Purchase, Care Setting |
5 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| GLP-1 THERAPY | 5.07 | 5.25 | 5.57 | 5.99 | 6.45 | 7.56 | 8.22 | 8.97 | 8.3 |
| GROWTH HORMONE THERAPY | 1.45 | 1.44 | 1.47 | 1.52 | 1.58 | 1.71 | 1.79 | 1.88 | 4.1 |
| INSULIN THERAPY | 66.5 | 69.52 | 74.51 | 80.85 | 87.95 | 105.01 | 115.31 | 127.06 | 9.3 |
| OSTEOPOROSIS | 4.06 | 4.19 | 4.42 | 4.73 | 5.08 | 5.9 | 6.39 | 6.94 | 7.8 |
| OTHER APPLICATIONS | 6.74 | 6.84 | 7.11 | 7.49 | 7.91 | 8.9 | 9.48 | 10.14 | 6.1 |
| TOTAL | 83.82 | 87.24 | 93.09 | 100.59 | 108.96 | 129.07 | 141.18 | 154.99 | 8.9 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| KINDRED HEALTHCARE INC. | United States | Private Company | Injectable and infusion-based delivery in LTAC hospitals,Oral drug administration in inpatient rehabilitation facilities,Contract rehabilitation and outpatient-related drug administration support, |
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | Turnkey automated manufacturing and assembly systems,Lifecycle services and digital/connected factory solutions,Contract manufacturing and value-added integration, |
| ALLERGAN PLC | Ireland | Private Company | Medical Aesthetics & Dermatology,Eye Care,Neuroscience & CNS, |
| CONSORT MEDICAL | United Kingdom | Private Company | Inhalation delivery devices,Injectable and autoinjector devices,Nasal and other specialty devices, |
| HENRY SCHEIN | United States | Public Company | Global Distribution & Value-Added Services,Global Specialty Products,Global Technology, |
| EMBECTA CORP. | United States | Public Company | Pen needles,Syringes,Safety injection devices, |
| NOVO NORDISK A/S | Denmark | Public Company | GLP-1 for Diabetes (injectable and oral),Obesity Care (GLP-1, including Wegovy pill),Insulin and Smart Pens (NovoPen 6, Echo Plus, needles), |
| YPSOMED | Switzerland | Public Company | Pen injectors,Auto-injectors,Wearable injectors and patch pumps, |
| TERUMO CORPORATION | Japan | Public Company | Cardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company, |
| NIPRO | Japan | Public Company | Dialysis products and artificial organ-related devices,Injection and infusion products, hospital and diabetic products,Pharmaceutical-related (generics, kits, CDMO for injectables and oral drugs), |
| ARKRAY, INC. | Japan | Private Company | Diabetes testing & blood glucose monitoring,Urinalysis,Immunodiagnostics, |
| HTL-STREFA | Poland | Private Company | Safety lancets for professional capillary sampling,Personal lancets for home blood glucose monitoring,Pen needles for diabetes therapy, |
| BERPU MEDICAL TECHNOLOGY CO., LTD. | China | Private Company | Regular insulin pen needles,Safety insulin pen needles and pens,Hypodermic and hypo-dermal needles, |
Kindred Healthcare Inc. is a United States-based private company founded in 1985 that operates with 64,200 employees. The company provides healthcare services and related solutions across the United States.
ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems for industrial applications.
Allergan PLC is an Ireland-based private company founded in 1983 with 17,400 employees. The company operates in the pharmaceutical and medical aesthetics sectors.
Consort Medical is a United Kingdom-based private company founded in 1938 with 2,000 employees. The company provides medical device and pharmaceutical delivery solutions.
Henry Schein is a United States-based public company founded in 1932 with 25,000 employees. The company is a distributor of healthcare products and services to medical, dental, and veterinary professionals.
Embecta Corp. is a United States-based public company founded in 1924 with 1,850 employees. The company manufactures and distributes diabetes care and medical devices.
Novo Nordisk A/S is a Denmark-based public company founded in 1923 with 67,900 employees. The company is a global pharmaceutical company specializing in diabetes, obesity, and other chronic diseases.
Ypsomed is a Switzerland-based public company founded in 1984 with 2,025 employees. The company develops and manufactures injection and infusion systems for diabetes and other therapeutic areas.
Terumo Corporation is a Japan-based public company founded in 1921 with 30,591 employees. The company manufactures and distributes medical devices, blood products, and pharmaceutical solutions globally.
Nipro is a Japan-based public company founded in 1947 with 38,593 employees. The company manufactures and supplies medical devices, pharmaceuticals, and healthcare products worldwide.
Arkray, Inc. is a Japan-based private company founded in 1960 with 566 employees. The company manufactures diagnostic and medical devices for healthcare applications.
HTL-Strefa is a Poland-based private company founded in 2000. The company manufactures medical devices and related healthcare products.
Berpu Medical Technology Co., Ltd. is a China-based private company founded in 2000. The company manufactures medical devices and related healthcare solutions.
The UK pen needles market was valued at $100.46 million in 2024 and is expected to grow to $166.32 million by 2029.
The UK pen needles market is projected to grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2029.
Key drivers include rising diabetes prevalence in the UK, increased adoption of injectable therapies, NHS modernization initiatives, and growing patient preference for convenient self-administration devices.
The UK represents a mature, high-value segment within Europe, characterized by strong regulatory frameworks, established NHS distribution networks, and significant investment in advanced pen needle technologies.
UK manufacturers are focusing on ultra-thin needle designs, safety-engineered features, and improved comfort profiles to meet evolving clinical standards and patient preferences.
This research study involved the extensive use of both primary and secondary sources. It involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
This research study involved the wide use of secondary sources such as directories, databases such as D&B Hoovers, Bloomberg Businessweek, and Factiva; white papers; and companies’ house documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the pen needles market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the pen needles market. Primary sources from the demand side included personnel from hospitals and clinics, researchers, lab technicians, purchase managers, and stakeholders from corporate & government bodies.
A breakdown of the primary respondents for the pen needles market (supply side) market is provided below:

Note 1: Companies are classified into tiers based on their total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
Note 2: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 3: Other primaries include sales managers, marketing managers, and product managers.
To know about the assumptions considered for the study, download the pdf brochure
The market size for pen needles was determined using data from four different sources, which will be discussed below. Each method was evaluated, and a weighted average was calculated based on the number of assumptions made by each approach. The market size for pen needles was ultimately derived from these three distinct sources, as detailed in the following sections.
Pen Needles Market: Bottom-up Approach & Top-down Approach

The entire market was divided into five segments to determine its size. Data triangulation and market breakdown processes were applied where necessary to complete the market engineering process and accurately arrive at the statistics for each segment.
To estimate the market size and forecast growth, secondary data from both paid and unpaid sources were utilized. A thorough analysis of the sales of pen needles from major players helped establish their market rankings. Due to data limitations, the revenue share for certain companies was calculated based on an in-depth examination of their product portfolios and individual sales performance. This information was verified at each stage through detailed interviews with industry professionals.
A pen needle is a hollow needle fixed within a plastic hub and connected to injectable pens. These pen needles come in various lengths and diameters, making them suitable for use by both healthcare professionals and patients to administer injectable medications. They are electro-polished to ensure smooth, thin, and fine-point tips, which enhance comfort and ease during penetration. Pen needles offer a modern alternative for drug delivery compared to traditional injection methods.
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Company Information
Geographic Analysis
Full forecast, segment splits, and company analysis for all Pen Needles Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report